Noninvasive imaging of apoptosis and its application in cancer therapeutics

被引:63
作者
Coppola, Julia M. [2 ]
Ross, Brian D. [1 ,2 ]
Rehemtulla, Alnawaz [1 ]
机构
[1] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA
关键词
D O I
10.1158/1078-0432.CCR-07-0782
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Activation of the apoptotic cascade plays an important role in the response of tumors to therapy. Noninvasive imaging of apoptosis facilitates optimization of therapeutic protocols regarding dosing and schedule and enables identification of efficacious combination therapies. Experimental Design: We describe a hybrid polypeptide that reports on caspase-3 activity in living cells and animals in a noninvasive manner. This reporter, ANLucBCLuc, constitutes a fusion of small interacting peptides, peptide A and peptide B, with the NLuc and CLuc fragments of luciferase with a caspase-3 cleavage site (DEVD) between pepANLuc (ANLuc) and pepBCLuc (BCLuc). During apoptosis, caspase-3 cleaves the reporter, enabling separation of ANLuc from BCLuc. A high-affinity interaction between peptide A and peptide B restores luciferase activity by NLuc and CLuc complementation. Using a D54 glioma model, we show the utility of the reporter in imaging of apoptosis in living subjects in response to various chemotherapy and radiotherapy regimens. Results: Treatment of live cells and mice carrying D54 tumor xenografts with chemotherapeutic agents such as temozolomide and perifosine resulted in induction of bioluminescence activity, which correlated with activation of caspase-3. Treatment of mice with combination therapy of temozolomide and radiation resulted in increased bioluminescence activity over individual treatments and increased therapeutic response due to enhanced apoptosis. Conclusion: The data provided show the utility of the ANLucBCLuc reporter in dynamic, noninvasive imaging of apoptosis and provides a rationale for use of this technology to optimize dose and schedule of novel therapies or to develop novel combination therapies using existing drugs.
引用
收藏
页码:2492 / 2501
页数:10
相关论文
共 42 条
[1]  
Bocangel DB, 2002, CLIN CANCER RES, V8, P2725
[2]   Opinion - The role of apoptosis in cancer development and treatment response [J].
Brown, JM ;
Attardi, LD .
NATURE REVIEWS CANCER, 2005, 5 (03) :231-237
[3]   Biochemical pathways of caspase activation during apoptosis [J].
Budihardjo, I ;
Oliver, H ;
Lutter, M ;
Luo, X ;
Wang, XD .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1999, 15 :269-290
[4]   Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms [J].
Chakravarti, Arnab ;
Erkkinen, Michael G. ;
Nestler, Ulf ;
Stupp, Roger ;
Mehta, Minesh ;
Aldape, Ken ;
Gilbert, Mark R. ;
Black, Peter McL. ;
Loeffler, Jay S. .
CLINICAL CANCER RESEARCH, 2006, 12 (15) :4738-4746
[5]   Food and Drug Administration drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme [J].
Cohen, MH ;
Johnson, JR ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :6767-6771
[6]   Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity [J].
Coppola, Julia M. ;
Hamilton, Christin A. ;
Bhojani, Mahaveer S. ;
Larsen, Martha J. ;
Ross, Brian D. ;
Rehemtulla, Alnawaz .
ANALYTICAL BIOCHEMISTRY, 2007, 364 (01) :19-29
[7]   Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours [J].
Crul, M ;
Rosing, H ;
de Klerk, GJ ;
Dubbelman, R ;
Traiser, M ;
Reichert, S ;
Knebel, NG ;
Schellens, JHM ;
Beijnen, JH ;
Huinink, WWT .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (12) :1615-1621
[8]   Cell death: Critical control points [J].
Danial, NN ;
Korsmeyer, SJ .
CELL, 2004, 116 (02) :205-219
[9]   Promoting apoptosis as a strategy for cancer drug discovery [J].
Fesik, SW .
NATURE REVIEWS CANCER, 2005, 5 (11) :876-885
[10]   THE BASIS FOR CURRENT TREATMENT RECOMMENDATIONS FOR MALIGNANT GLIOMAS [J].
FINE, HA .
JOURNAL OF NEURO-ONCOLOGY, 1994, 20 (02) :111-120